January 06, 2021
The Fourth Circuit on Wednesday reversed a $1.25 million verdict against Boehringer Ingelheim in a suit over the bleeding risks of its blood thinner Pradaxa, finding that fraud claims brought by the family of a deceased woman were preempted by federal law.